VOCERYQ FDA Accelerated Approval - INOVIO Investor Call - INOVIO PHARMACEUTICALS INC

Financial Performance:

• No specific historical revenue or earnings figures were disclosed as the product is newly approved; Inovio is currently a pre-commercial/early commercial stage company.
• Pricing is set at approximately $115,000 per dose, totaling $460,000 for the complete four-dose series, consistent with existing immunotherapy pricing for RRP.
• Current cash reserves are sufficient to fund operations through the launch period and into the first quarter of 2027.
• The company is actively evaluating capital raising strategies to fully fund the commercial launch beyond Q1 2027.
• Revenue recognition is standard, recorded when the product is received at the end location.

Guidance and Future Outlook:

• Product availability and shipping are expected to commence within approximately 60 days of approval.
• Full commercial field deployment is targeted for the first quarter of 2027.
• Reimbursement coverage for approximately 80% of U.S. patients is projected to be established within nine months of approval.
• A confirmatory study protocol will be submitted before the end of the year, with final alignment expected by mid-next year.
• Long-term goals include expanding into pediatric indications, exploring continued treatment strategies, and pursuing international markets (EU, UK).
• Pipeline advancement includes seeking partnerships for next-generation protein replacement therapies for genetic diseases like Hemophilia A and Fabry disease.

Business Segments and Product Lines:

• Primary Product: Voseric (formerly Placeric/INO7107), the first FDA-approved plasmid DNA-based immunotherapy for Recurrent Respiratory Papillomatosis (RRP).
• Indication: Broad adult indication to reduce the frequency of surgeries; previously focused on patients with 3+ surgeries in the prior 12 months for accelerated approval analysis.
• Mechanism: A dual-plasmid DNA vaccine encoding HPV 6/11 E6/E7 proteins and human IL-12, delivered via the proprietary Selectra electroporation device.
• Clinical Data: 27% of patients with severe disease (median 4.5 prior surgeries) achieved complete response (zero surgeries) in the first year; efficacy data published in Nature Communications and Laryngoscope.
• Manufacturing: Inventory and capacity are secured to meet demand through at least 2027.

Market and Competitive Landscape:

• Target Population: Estimated prevalent adult RRP population of at least 25,000 in the U.S., with a significant unmet need as few have received immunotherapy.
• Competitive Differentiation: Voseric does not require scoping or surgery to remove papillomas during the dosing window, unlike some competitors; focuses on reducing the cumulative burden of surgery.
• Target Audience: Approximately 400 laryngologists treat the vast majority of patients; 80% of care is concentrated in ~100 Integrated Delivery Networks (IDNs) and academic institutions.
• Guideline Support: The RRP Foundation position paper recommends immunotherapy as a first-line treatment to prevent vocal cord damage.

Risks and Challenges:

• Regulatory: Continued approval is contingent on the successful completion and positive results of the planned confirmatory study (enrollment of 50+ patients, 3-year follow-up).
• Commercial: Potential delays in reimbursement code (J-code) acquisition or payer formulary acceptance.
• Market Adoption: Success depends on rapid adoption by laryngologists to shift from the decades-old standard of surgical debulking to immunotherapy.
• Financial: Need for additional capital infusion after Q1 2027 to sustain launch and commercial operations.

Management Commentary and Tone:

• Management expressed high confidence and optimism, labeling the approval a "landmark moment" and a "validation of the DNA medicine platform."
• Tone emphasizes patient-centricity, repeatedly highlighting the reduction of surgery as the primary value proposition.
• CEO Dr. Jackie Shea and CMO Dr. Mike Sumner framed the approval as a pivotal step for the broader pipeline and future product launches.
• Commercial leadership emphasized a "highly focused" launch strategy to ensure rapid patient access.

Analyst Questions and Answers:

• Addressable Market: CFO Steve Ege clarified the 25,000 figure refers to adults; pediatric population is separate and not included in the current label.
• Efficacy Comparison: Management addressed lower Complete Response (CR) rates compared to other drugs by explaining the unique trial design that avoids surgeries during the dosing window, which they argue reflects true clinical benefit and patient preference.
• Confirmatory Study Details: Confirmed the study will include both adult and pediatric patients (starting with adolescents) and requires 3 years of efficacy data to convert to traditional approval.
• Commercial Structure: Launch utilizes 20 key account manager territories supported by Medical Science Liaisons (MSLs) and reimbursement specialists via partner CINEOS Health.
• Revenue Recognition: Confirmed as standard practice upon delivery to the end location.

Other Key Points:

• Label Specifics: The approved label applies to all adults with RRP, though the accelerated approval decision was driven by data from the severe subgroup (3+ prior surgeries).
• Safety Profile: Generally well-tolerated with low-grade adverse events (injection site pain, fatigue); supported by data from VGX3100 program (1,100+ administrations).
• Logistics: Product requires standard refrigeration and has a three-year shelf life, facilitating office-based administration.
• Support Program: A dedicated "Voseric Support Program" will be launched to handle ordering, benefits verification, and patient assistance to minimize administrative burden.